| 001 | 877590 | ||
| 005 | 20210130005134.0 | ||
| 024 | 7 | _ | |a 10.1038/s41420-020-0258-3 |2 doi |
| 024 | 7 | _ | |a 2128/25101 |2 Handle |
| 024 | 7 | _ | |a altmetric:80043886 |2 altmetric |
| 024 | 7 | _ | |a pmid:32337072 |2 pmid |
| 024 | 7 | _ | |a WOS:000526352700001 |2 WOS |
| 037 | _ | _ | |a FZJ-2020-02312 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Koch, Katharina |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity |
| 260 | _ | _ | |a London |c 2020 |b Nature Publishing Group816700 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1592490604_21100 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Cancer cells upregulate anabolic processes to maintain high rates of cellular turnover. Limiting the supply ofmacromolecular precursors by targeting enzymes involved in biosynthesis is a promising strategy in cancer therapy.Several tumors excessively metabolize glutamine to generate precursors for nonessential amino acids, nucleotides,and lipids, in a process called glutaminolysis. Here we show that pharmacological inhibition of glutaminase (GLS)eradicates glioblastoma stem-like cells (GSCs), a small cell subpopulation in glioblastoma (GBM) responsible for therapyresistance and tumor recurrence. Treatment with small molecule inhibitors compound 968 and CB839 effectivelydiminished cell growth and in vitro clonogenicity of GSC neurosphere cultures. However, our pharmaco-metabolicstudies revealed that only CB839 inhibited GLS enzymatic activity thereby limiting the influx of glutamine derivatesinto the TCA cycle. Nevertheless, the effects of both inhibitors were highly GLS specific, since treatment sensitivitymarkedly correlated with GLS protein expression. Strikingly, we found GLS overexpressed in in vitro GSC models ascompared with neural stem cells (NSC). Moreover, our study demonstrates the usefulness of in vitro pharmaco-metabolomics to score target specificity of compounds thereby refining drug development and risk assessment. |
| 536 | _ | _ | |a 552 - Engineering Cell Function (POF3-552) |0 G:(DE-HGF)POF3-552 |c POF3-552 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Hartmann, Rudolf |0 P:(DE-Juel1)132001 |b 1 |u fzj |
| 700 | 1 | _ | |a Tsiampali, Julia |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Uhlmann, Constanze |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Nickel, Ann-Christin |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a He, Xiaoling |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Kamp, Marcel A. |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Sabel, Michael |0 P:(DE-Juel1)165921 |b 7 |
| 700 | 1 | _ | |a Barker, Roger A. |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Steiger, Hans-Jakob |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Hänggi, Daniel |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 11 |
| 700 | 1 | _ | |a Maciaczyk, Jaroslaw |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Kahlert, Ulf D. |0 P:(DE-HGF)0 |b 13 |e Corresponding author |
| 773 | _ | _ | |a 10.1038/s41420-020-0258-3 |g Vol. 6, no. 1, p. 20 |0 PERI:(DE-600)2842546-7 |n 1 |p 20 |t Cell death discovery |v 6 |y 2020 |x 2058-7716 |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/877590/files/A%20comparative%20pharmaco-metabolomic%20study%20ofglutaminase%20inhibitors%20in%20glioma%20stem-like%20cellsconfirms%20biological%20effectiveness%20but%20revealsdifferences%20in%20target-specificity.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://juser.fz-juelich.de/record/877590/files/A%20comparative%20pharmaco-metabolomic%20study%20ofglutaminase%20inhibitors%20in%20glioma%20stem-like%20cellsconfirms%20biological%20effectiveness%20but%20revealsdifferences%20in%20target-specificity.pdf?subformat=pdfa |
| 909 | C | O | |o oai:juser.fz-juelich.de:877590 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)132001 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 11 |6 P:(DE-Juel1)132029 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |1 G:(DE-HGF)POF3-550 |0 G:(DE-HGF)POF3-552 |2 G:(DE-HGF)POF3-500 |v Engineering Cell Function |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-01-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-01-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2020-01-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-01-11 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2020-01-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2020-01-11 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-01-11 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2020-01-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-01-11 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2020-01-11 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |f 2020-01-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-01-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-01-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-01-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2020-01-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-01-11 |
| 920 | 1 | _ | |0 I:(DE-Juel1)IBI-7-20200312 |k IBI-7 |l Strukturbiochemie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::